MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
1.105
-0.035
-3.07%
Opening 14:56 12/01 EST
OPEN
1.120
PREV CLOSE
1.140
HIGH
1.140
LOW
1.070
VOLUME
499.24K
TURNOVER
0
52 WEEK HIGH
2.040
52 WEEK LOW
0.6700
MARKET CAP
192.68M
P/E (TTM)
-7.9726
1D
5D
1M
3M
1Y
5Y
Rigel Pharmaceuticals: Push To Profitability Continues, But COVID Beacon Seems Extinguished
Rigel pharmaceuticals, inc. (nasdaq:rigl) is a strong buy based on the revenue growth of tavalisse and other clinical catalysts. Rigl's net loss narrowed to $5.7m in q3'23. The company's trial of fostamatinib in covid seems to have failed to meet the primary endpoint. I have written off the possibility of success in the covid trial. The patent infringement suit with annora pharma is in play, but the case will take time.
Seeking Alpha · 1d ago
Rigel Pharmaceuticals Inc: Current report
Press release · 1d ago
Weekly Report: what happened at RIGL last week (1120-1124)?
Weekly Report · 5d ago
Best Momentum Stocks to Buy for November 22nd
NASDAQ · 11/22 15:00
New Strong Buy Stocks for November 22nd
NASDAQ · 11/22 11:23
Weekly Report: what happened at RIGL last week (1113-1117)?
Weekly Report · 11/20 09:04
Rigel Pharma To Present At The Jefferies London Healthcare Conference; Webcast At 10:30 AM ET
NASDAQ · 11/14 14:29
Weekly Report: what happened at RIGL last week (1106-1110)?
Weekly Report · 11/13 09:04
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing therapies that improve the lives of patients with hematologic disorders and cancer. The Company's lead product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its product also includes REZLIDHIA (olutasidenib) capsules, which are for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Its other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development. In addition, it has product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.